Evaluate the Safety Profile of BGF MDI in Chinese Patients with COPD in Routine Clinical Practice - TORES

Study identifier:D5980R00016

ClinicalTrials.gov identifier:NCT04536402

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multi-centre, Prospective, Observational Post-Authorization Safety Study to Evaluate the Safety Profile of Budesonide/Glycopyrrolate/Formoterol MDI in Chinese Patients with COPD in Routine Clinical Practice

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

3520

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 16 Mar 2021
Primary Completion Date: 08 Nov 2023
Study Completion Date: 08 Nov 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria